Publicaciones en colaboración con investigadores/as de Hospital General Universitario Gregorio Marañón (30)

2022

  1. Author Correction: Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension (Scientific Reports, (2022), 12, 1, (5289), 10.1038/s41598-022-09353-z)

    Scientific Reports

  2. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

    npj Genomic Medicine, Vol. 7, Núm. 1

  3. Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension

    Scientific reports, Vol. 12, Núm. 1, pp. 5289

2021

  1. HLA association with the susceptibility to anti-synthetase syndrome

    Joint Bone Spine, Vol. 88, Núm. 3

  2. Immune thrombocytopenia and COVID-19: Case report and review of literature

    Lupus, Vol. 30, Núm. 9, pp. 1515-1521

  3. Role of MUC1 rs4072037 polymorphism and serum KL-6 levels in patients with antisynthetase syndrome

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease

    Scientific Reports, Vol. 10, Núm. 1

  2. Influence of MUC5B gene on antisynthetase syndrome

    Scientific Reports, Vol. 10, Núm. 1

  3. Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practice

    Clinical and experimental rheumatology, Vol. 38, Núm. 2, pp. 112-119

2019

  1. GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways

    Nature Communications, Vol. 10, Núm. 1

  2. Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course

    Journal of Clinical Medicine, Vol. 8, Núm. 11

  3. Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice

    Seminars in Arthritis and Rheumatism, Vol. 49, Núm. 1, pp. 126-135

2018

  1. Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet's Disease

    Ophthalmology, Vol. 125, Núm. 9, pp. 1444-1451

  2. Timing of onset affects arthritis presentation pattern in antisynthetase syndrome

    Clinical and Experimental Rheumatology, Vol. 36, Núm. 1, pp. 44-49

2017

  1. Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study

    Autoimmunity Reviews, Vol. 16, Núm. 3, pp. 253-257

  2. Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group

    Clinical Reviews in Allergy and Immunology, Vol. 52, Núm. 1, pp. 71-80

2016

  1. Groove sign

    European Journal of Internal Medicine, Vol. 28, pp. e3-e4

  2. LILRA3 deficiency is not involved in the giant cell arteritis and systemic sclerosis predisposition

    Clinical and Experimental Rheumatology

2015

  1. Clinical spectrum time course in anti jo-1 positive antisynthetase syndrome: Results from an international retrospective multicenter study

    Medicine (United States), Vol. 94, Núm. 32

  2. Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis

    Clinical and Experimental Rheumatology, Vol. 33, pp. 31-35